text_1: 在 既往 接受 过 大量 治疗 , 患 慢性期 或 加速 期 CML , 并且 现有 ATP 竞争性 TKI 治疗 失败 的 患者 人群 中 , asciminib 具有 显著 的 持久 临床 活性 .
  
text_2: asciminib had substantial and durable clinical activity in a heavily pretreated population of patients with chronic @-@ phase or accelerated @-@ phase CML in whom treatment with currently available ATP @-@ competitive TKIs had failed .
  